Matthew H G Katz

List of Publications by Year
in descending order

186 papers	8,969 citations	53939 47 h-index	53065 89 g-index
190 all docs	190 docs citations	190 times ranked	7549 citing authors

#	Article	IF	Citations
1	Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease. Journal of the American College of Surgeons, 2008, 206, 833-846.	0.2	740
2	Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer, 2012, 118, 5749-5756.	2.0	457
3	International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology, 2018, 18, 2-11.	0.5	452
4	Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2009, 16, 836-47.	0.7	435
5	Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer. JAMA Surgery, 2016, 151, e161137.	2.2	365
6	Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design. Annals of Surgical Oncology, 2013, 20, 2787-2795.	0.7	302
7	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2541-2556.	0.8	302
8	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1692-1697.	3.3	237
9	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Journal of the National Cancer Institute, 2019, 111, 782-794.	3.0	223
10	Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival. Journal of Gastrointestinal Surgery, 2014, 18, 16-25.	0.9	172
11	Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer, 2017, 17, 505.	1.1	166
12	Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. Hpb, 2014, 16, 430-438.	0.1	151
13	Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2019, 37, 2082-2088.	0.8	135
14	Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation. Annals of Surgical Oncology, 2010, 17, 1794-1801.	0.7	129
15	Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Annals of Surgical Oncology, 2015, 22, 2416-2423.	0.7	125
16	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Journal of Gastrointestinal Surgery, 2017, 21, 164-174.	0.9	124
17	Selective Reoperation for Locally Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma Following Primary Pancreatic Resection. Journal of Gastrointestinal Surgery, 2012, 16, 1696-1704.	0.9	109
18	Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer. Annals of Surgical Oncology, 2015, 22, 1168-1175.	0.7	108

#	Article	IF	Citations
19	Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas. JAMA Oncology, 2022, 8, 1263.	3.4	107
20	Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2020, 155, 832.	2.2	105
21	Tumor-Node-Metastasis Staging of Pancreatic Adenocarcinoma. Ca-A Cancer Journal for Clinicians, 2008, 58, 111-125.	157.7	103
22	Radiographic Tumorâ€“Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2014, 18, 269-278.	0.9	102
23	Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.. Journal of Clinical Oncology, 2021, 39, 377-377.	0.8	100
24	Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2012, 16, 68-79.	0.9	98
25	Comprehensive geriatric assessment of risk factors associated with adverse outcomes and resource utilization in cancer patients undergoing abdominal surgery. Journal of Surgical Oncology, 2013, 108, 182-186.	0.8	98
26	Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy. Annals of Surgical Oncology, 2012, 19, 2045-2053.	0.7	96
27	Efficacy of Salmonella typhimurium A1â€R Versus Chemotherapy on a Pancreatic Cancer Patientâ€Derived Orthotopic Xenograft (PDOX). Journal of Cellular Biochemistry, 2014, 115, 1254-1261.	1.2	93
28	Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?. Journal of Gastrointestinal Surgery, 2015, 19, 80-87.	0.9	92
29	Anatomy of the Superior Mesenteric Vein With Special Reference to the Surgical Management of First-order Branch Involvement at Pancreaticoduodenectomy. Annals of Surgery, 2008, 248, 1098-1102.	2.1	83
30	Metastatic Recurrence in a Pancreatic Cancer Patient Derived Orthotopic Xenograft (PDOX) Nude Mouse Model Is Inhibited by Neoadjuvant Chemotherapy in Combination with Fluorescence-Guided Surgery with an Anti-CA 19-9-Conjugated Fluorophore. PLoS ONE, 2014, 9, e114310.	1.1	82
31	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2017, 152, 1048.	2.2	82
32	Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. Hpb, 2012, 14, 365-372.	0.1	77
33	Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial. Annals of Surgical Oncology, 2011, 18, 337-344.	0.7	72
34	Home-Based Exercise Prehabilitation During Preoperative Treatment for Pancreatic Cancer Is Associated With Improvement in Physical Function and Quality of Life. Integrative Cancer Therapies, 2019, 18, 153473541989406.	0.8	72
35	Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. British Journal of Cancer, 2017, 116, 697-702.	2.9	70
36	Selective efficacy of zoledronic acid on metastasis in a patientâ€derived orthotopic xenograph (PDOX) nudeâ€mouse model of human pancreatic cancer. Journal of Surgical Oncology, 2015, 111, 311-315.	0.8	69

#	Article	IF	Citations
37	Adenosquamous Versus Adenocarcinoma of the Pancreas: A Population-Based Outcomes Analysis. Journal of Gastrointestinal Surgery, 2011, 15, 165-174.	0.9	64
38	Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis. Annals of Surgical Oncology, 2013, 20, 2197-2203.	0.7	61
39	Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Annals of Surgery, 2021, 273, 806-813.	2.1	61
40	Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas. Journal of Gastrointestinal Surgery, 2016, 20, 1966-1974.	0.9	60
41	Retroperitoneal Dissection in Patients with Borderline Resectable Pancreatic Cancer: Operative Principles and Techniques. Journal of the American College of Surgeons, 2012, 215, e11-e18.	0.2	59
42	Management of Borderline Resectable Pancreatic Cancer. Seminars in Radiation Oncology, 2014, 24, 105-112.	1.0	59
43	Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy. Annals of Surgical Oncology, 2015, 22, 3522-3529.	0.7	58
44	Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma. Pancreas, 2019, 48, 216-222.	0.5	56
45	Home-based exercise during preoperative therapy for pancreatic cancer. Langenbeck's Archives of Surgery, 2017, 402, 1175-1185.	0.8	52
46	Morbidity and Mortality after Pancreaticoduodenectomy in Patients with Borderline Resectable Type C Clinical Classification. Journal of Gastrointestinal Surgery, 2014, 18, 146-156.	0.9	51
47	Fear of Cancer Recurrence after Curative Pancreatectomy: A Cross-sectional Study in Survivors of Pancreatic and Periampullary Tumors. Annals of Surgical Oncology, 2012, 19, 4078-4084.	0.7	49
48	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer, 2016, 122, 2671-2679.	2.0	49
49	Clinical Calculator of Conditional Survival Estimates for Resected and Unresected Survivors of Pancreatic Cancer. Archives of Surgery, 2012, 147, 513-9.	2.3	48
50	Physical activity and exercise during preoperative pancreatic cancer treatment. Supportive Care in Cancer, 2019, 27, 2275-2284.	1.0	45
51	The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Annals of Surgical Oncology, 2015, 22, 1221-1228.	0.7	44
52	Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients. Scientific Reports, 2019, 9, 13966.	1.6	43
53	Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Journal of Gastrointestinal Surgery, 2016, 20, 1975-1985.	0.9	42
54	Risk-stratified clinical pathways decrease the duration of hospitalization and costs of perioperative care after pancreatectomy. Surgery, 2018, 164, 424-431.	1.0	41

#	Article	IF	Citations
55	High G2M Pathway Score Pancreatic Cancer is Associated with Worse Survival, Particularly after Margin-Positive (R1 or R2) Resection. Cancers, 2020, 12, 2871.	1.7	41
56	Selective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis. Journal of Gastrointestinal Surgery, 2017, 21, 636-646.	0.9	39
57	Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. Journal of Gastrointestinal Surgery, 2018, 22, 703-712.	0.9	39
58	Role of Neoadjuvant Therapy in the Multimodality Treatment of Older Patients with Pancreatic Cancer. Journal of the American College of Surgeons, 2014, 219, 111-120.	0.2	36
59	Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Medicine, 2021, 10, 5041-5050.	1.3	35
60	APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Nature Cancer, 2021, 2, 1338-1356.	5.7	35
61	Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here?. Annals of Surgical Oncology, 2011, 18, 608-610.	0.7	34
62	Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2017, 21, 155-163.	0.9	34
63	Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Annals of Surgery, 2020, 271, 996-1002.	2.1	34
64	Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Annals of Surgical Oncology, 2018, 25, 1709-1715.	0.7	32
65	Association between frailty syndrome and survival in patients with pancreatic adenocarcinoma. Cancer Medicine, 2019, 8, 2867-2876.	1.3	32
66	Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Annals of Surgical Oncology, 2017, 24, 2031-2039.	0.7	30
67	Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Surgery, 2017, 162, 557-567.	1.0	30
68	Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer. JAMA Surgery, 2021, 156, 663.	2.2	30
69	A High Positive Lymph Node Ratio is Associated with Distant Recurrence after Surgical Resection of Ampullary Carcinoma. Journal of Gastrointestinal Surgery, 2012, 16, 2056-2063.	0.9	29
70	Pancreatic neuroendocrine tumors. Current Opinion in Gastroenterology, 2019, 35, 468-477.	1.0	29
71	Early postoperative drain fluid amylase in risk-stratified patients promotes tailored post-pancreatectomy drain management and potential for accelerated discharge. Surgery, 2020, 167, 442-447.	1.0	29
72	Current concepts in multimodality therapy for retroperitoneal sarcoma. Expert Review of Anticancer Therapy, 2007, 7, 159-168.	1.1	28

#	Article	IF	Citations
73	Impact of pancreatectomy on longâ€term patientâ€reported symptoms and quality of life in recurrenceâ€free survivors of pancreatic and periampullary neoplasms. Journal of Surgical Oncology, 2017, 115, 144-150.	0.8	28
74	Current Status of Adjuvant Therapy for Pancreatic Cancer. Oncologist, 2010, 15, 1205-1213.	1.9	26
75	Role and Operative Technique of Portal Venous Tumor Thrombectomy in Patients with Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2015, 19, 2011-2018.	0.9	26
76	Cancer Surgery Scheduling During and After the COVID-19 First Wave. Annals of Surgery, 2020, 272, e106-e111.	2.1	26
77	Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2017, 152, 1086.	2.2	25
78	Treatment of Borderline Resectable Pancreatic Cancer. Current Treatment Options in Oncology, 2013, 14, 293-310.	1.3	24
79	Transcriptomic Profile of Lymphovascular Invasion, a Known Risk Factor of Pancreatic Ductal Adenocarcinoma Metastasis. Cancers, 2020, 12, 2033.	1.7	24
80	An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. Endoscopic Ultrasound, 2020, 9, 24.	0.6	23
81	Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas, 2019, 48, 837-843.	0.5	22
82	Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Cancer Discovery, 2022, 12, 2330-2349.	7.7	22
83	Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 307-313.	2.9	21
84	Clinical Factors Associated With Practice Variation in Discharge Opioid Prescriptions After Pancreatectomy. Annals of Surgery, 2020, 272, 163-169.	2.1	21
85	Adherence with operative standards in the treatment of gastric cancer in the United States. Gastric Cancer, 2020, 23, 550-560.	2.7	21
86	Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial. Annals of Surgical Oncology, 2011, 18, 3615-3622.	0.7	20
87	Outpatient virtual clinical encounters after complex surgery for cancer: a prospective pilot study of â€œTeleDischargeâ€. Journal of Surgical Research, 2016, 202, 196-203.	0.8	20
88	A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer. Cancers, 2020, 12, 3635.	1.7	20
89	The Role of Home-Based Exercise in Maintaining Skeletal Muscle During Preoperative Pancreatic Cancer Treatment. Integrative Cancer Therapies, 2021, 20, 153473542098661.	0.8	20
90	FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. Journal of the National Cancer Institute, 2022, 114, 695-703.	3.0	20

#	Article	IF	Citations
91	Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. Journal of Oncology Practice, 2017, 13, 388-391.	2.5	19
92	Computed Tomographyâ€“Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precision Oncology, 2019, 3, 1-15.	1.5	19
93	Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with thrombosis. Journal of Surgical Oncology, 2018, 117, 1648-1654.	0.8	18
94	Pancreaticoduodenectomy with vascular resection for pancreatic head adenocarcinoma. Expert Review of Anticancer Therapy, 2014, 14, 919-929.	1.1	17
95	Risk-Stratified Pancreatectomy Clinical Pathway Implementation and Delayed Gastric Emptying. Journal of Gastrointestinal Surgery, 2021, 25, 2221-2230.	0.9	17
96	The Landmark Series: Preoperative Therapy for Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 4104-4129.	0.7	17
97	Supports and Barriers to Home-Based Physical Activity During Preoperative Treatment of Pancreatic Cancer: A Mixed-Methods Study. Journal of Physical Activity and Health, 2019, 16, 1113-1122.	1.0	17
98	Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.. Journal of Clinical Oncology, 2015, 33, 4008-4008.	0.8	17
99	Response to Preoperative Therapy in Localized Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 516.	1.3	16
100	Adoption of Telemedicine for Postoperative Follow-Up After Inpatient Cancer-Related Surgery. JCO Oncology Practice, 2022, 18, e1091-e1099.	1.4	16
101	Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 783-791.e1.	2.3	16
102	Inpatient Opioid Use After Pancreatectomy: Opportunities for Reducing Initial Opioid Exposure in Cancer Surgery Patients. Annals of Surgical Oncology, 2019, 26, 3428-3435.	0.7	15
103	Overall Body Composition and Sarcopenia Are Associated with Poor Liver Hypertrophy Following Portal Vein Embolization. Journal of Gastrointestinal Surgery, 2021, 25, 405-410.	0.9	15
104	Factors Influencing Exercise Following Pancreatic Tumor Resection. Annals of Surgical Oncology, 2021, 28, 2299-2309.	0.7	15
105	The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma. American Journal of Surgery, 2019, 218, 145-150.	0.9	14
106	Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. Journal of Gastrointestinal Surgery, 2020, 24, 368-379.	0.9	14
107	Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 4615-4622.	0.7	14
108	A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer. Annals of Surgery, 2021, 274, e82-e84.	2.1	14

#	Article	IF	Citations
109	Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers, 2021, 13, 6022.	1.7	14
110	Preoperative therapy for pancreatic adenocarcinomaâ€"precision beyond anatomy. Cancer, 2022, 128, 3041-3056.	2.0	14
111	Opioid-prescribing Practices After Oncologic Surgery. Annals of Surgery, 2020, 271, e9-e10.	2.1	13
112	Surgical Outcomes in Cancer Patients Undergoing Elective Surgery After Recovering from Mild-to-Moderate SARS-CoV-2 Infection. Annals of Surgical Oncology, 2021, 28, 8046-8053.	0.7	13
113	Iterative Changes in Risk-Stratified Pancreatectomy Clinical Pathways and Accelerated Discharge After Pancreaticoduodenectomy. Journal of Gastrointestinal Surgery, 2022, 26, 1054-1062.	0.9	13
114	The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 3939-3947.	0.7	12
115	The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. Urology, 2017, 108, 114-121.	0.5	11
116	Educating surgical oncology providers on perioperative opioid use: A departmental survey 1 year after the intervention. Journal of Surgical Oncology, 2020, 122, 547-554.	0.8	11
117	Defining and Treating Borderline Resectable Pancreatic Cancer. Current Treatment Options in Oncology, 2020, 21, 71.	1.3	11
118	Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Cancers, 2020, 12, 3656.	1.7	11
119	Radiotherapy for Resectable and Borderline Resectable Pancreas Cancer: When and Why?. Journal of Gastrointestinal Surgery, 2021, 25, 843-848.	0.9	11
120	Borderline resectable pancreatic cancerâ€"At the crossroads of precision medicine. Cancer, 2019, 125, 1584-1587.	2.0	10
121	Sustained reduction in discharge opioid volumes through provider education: Results of 1168 cancer surgery patients over 2 years. Journal of Surgical Oncology, 2021, 124, 143-151.	0.8	10
122	Developing a Value Framework: Utilizing Administrative Data to Assess an Enhanced Care Initiative. Journal of Surgical Research, 2021, 262, 115-120.	0.8	10
123	Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, 4125-4125.	0.8	10
124	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives. Endocrine-Related Cancer, 2020, 27, T9-T25.	1.6	10
125	What is â€œValueâ€? Results of a Survey of Cancer Patients and Providers. Annals of Surgical Oncology, 2022, 29, 6537-6545.	0.7	10
126	Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. Journal of Surgical Research, 2019, 243, 90-99.	0.8	9

#	Article	IF	Citations
127	Postoperative pancreatic fistula after distal pancreatectomy for non-pancreas retroperitoneal tumor resection. American Journal of Surgery, 2020, 220, 140-146.	0.9	9
128	Frequency of Sarcopenia, Sarcopenic Obesity, and Changes in Physical Function in Surgical Oncology Patients Referred for Prehabilitation. Integrative Cancer Therapies, 2021, 20, 153473542110001.	0.8	9
129	Communicating Value: Use of a Novel Framework in the Assessment of an Enhanced Recovery Initiative. Annals of Surgery, 2021, 273, e7-e9.	2.1	9
130	First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 619-627.	0.7	8
131	Pancreaticoduodenectomy with Mesocaval Shunt for Locally Advanced Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 652-652.	0.7	8
132	Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 1563-1569.	0.7	8
133	Universal preoperative SARS-CoV-2 testing can facilitate safe surgical treatment during local COVID-19 surges. British Journal of Surgery, 2021, 108, e24-e26.	0.1	8
134	Technical Standards for Cancer Surgery: Commission on Cancer Standards 5.3â€“5.8. Annals of Surgical Oncology, 2022, , 1.	0.7	7
135	Laparoscopic Insulinoma Enucleation from the Retro-Pancreatic Neck: A Stepwise Approach. Annals of Surgical Oncology, 2016, 23, 2001-2001.	0.7	6
136	Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard?. Annals of Surgery, 2018, 268, 223-224.	2.1	6
137	Quality of life impact of EUS in patients at risk for developing pancreatic cancer. Endoscopic Ultrasound, 2020, 9, 53.	0.6	6
138	Borderline resectable pancreatic cancer: pushing the technical limits of surgery. Bulletin of the American College of Surgeons, 2013, 98, 61-3.	0.3	6
139	Risk-stratified posthepatectomy pathways based upon the Kawaguchiâ€“Gayet complexity classification and impact on length of stay. Surgery Open Science, 2022, 9, 109-116.	0.5	6
140	External Retraction Technique for Robotic Pancreatoduodenectomy. Journal of the American College of Surgeons, 2020, 231, e8-e10.	0.2	5
141	Perceptions of opioid use and prescribing habits in oncologic surgery: A survey of the society of surgical oncology membership. Journal of Surgical Oncology, 2020, 122, 1066-1073.	0.8	5
142	Current Controversies in the Stage-Specific Multidisciplinary Management of Pancreatic Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e157-e164.	1.8	5
143	Multimodality management of borderline resectable pancreatic adenocarcinoma. Chinese Clinical Oncology, 2017, 6, 27-27.	0.4	5
144	PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. BMC Cancer, 2022, 22, 14.	1.1	5

#	Article	IF	Citations
145	Baseline CT-based Radiomic Features Aid Prediction of Nodal Positivity after Neoadjuvant Therapy in Pancreatic Cancer. Radiology Imaging Cancer, 2022, 4, e210068.	0.7	5
146	Comparative analysis of opioid use between robotic and open pancreatoduodenectomy. Journal of Hepato-Biliary-Pancreatic Sciences, 2023, 30, 523-531.	1.4	5
147	Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization. Hpb, 2019, 21, 841-848.	0.1	4
148	Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles. Annals of Surgical Oncology, 2020, 27, 2269-2275.	0.7	4
149	Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. Journal of Surgical Oncology, 2021, 124, 1381-1389.	0.8	4
150	Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results. Bulletin of the American College of Surgeons, 2015, 100, 39-41.	0.3	4
151	Spleen and splenic vessel preserving distal pancreatectomy for bifocal PNET in a young patient with MEN1. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 4619-4619.	1.3	3
152	History of preoperative therapy for pancreatic cancer and the MD Anderson experience. Journal of Surgical Oncology, 2021, 123, 1414-1422.	0.8	3
153	Evaluation of the reporting quality of clinical practice guidelines on pancreatic cancer using the RIGHT checklist. Annals of Translational Medicine, 2021, 9, 1088-1088.	0.7	3
154	GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. Pancreatology, 2021, 21, 1378-1385.	0.5	3
155	Early Experience of a Robotic Foregut Surgery Program at a Cancer Center: Video of Shared Steps in Robotic Pancreatoduodenectomy and Gastrectomy. Annals of Surgical Oncology, 2022, 29, 285-285.	0.7	3
156	Contemporary Assessment of Need for Palliative Bypass After Aborted Pancreatoduodenectomy Following Neoadjuvant Therapy. Journal of Gastrointestinal Surgery, 2022, 26, 352-359.	0.9	3
157	Association of Patient Controlled Analgesia and Total Inpatient Opioid Use After Pancreatectomy. Journal of Surgical Research, 2022, 275, 244-251.	0.8	3
158	A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients. Surgery Open Science, 2022, 9, 51-57.	0.5	3
159	Opioid Discharge Prescriptions After Inpatient Surgery: Risks of Rebound Refills by Length of Stay. Journal of Surgical Research, 2022, 278, 111-118.	0.8	3
160	Prognostic significance of preoperative and postoperative CA 19â€9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first. Journal of Surgical Oncology, 2022, 126, 1021-1027.	0.8	3
161	Perioperative Therapy for Borderline Resectable Pancreatic Cancer: What and When?. Annals of Surgical Oncology, 2019, 26, 1596-1597.	0.7	2
162	Clinical trialsâ€”Designing, implementing, and collaborating. Journal of Surgical Oncology, 2020, 122, 25-28.	0.8	2

#	Article	IF	Citations
163	Abstract CT220: A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with Pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic canc. Cancer Research, 2015, 75, CT220-CT220.	0.4	2
164	Robotic Duodenojejunostomy Bypass for Metastatic Pancreatic Body Cancer. Journal of Gastrointestinal Surgery, 2022, 26, 1115-1116.	0.9	2
165	ASO Author Reflections: Technical Standards for Cancer Surgery: From â€œHow I Do Itâ€• to â€œHow We Do Itâ€: Annals of Surgical Oncology, 2022, 29, 6559-6560.	0.7	2
166	Preoperative Therapy for Pancreatic Cancer: The Tide Is Turning. Journal of Oncology Practice, 2016, 12, 783-784.	2.5	1
167	Should Fear of Adverse Events Influence the Decision to Administer Preoperative Therapy to Patients with Pancreatic Cancer?. Annals of Surgical Oncology, 2018, 25, 588-590.	0.7	1
168	Improving Outcomes After Distal Pancreatectomy with Celiac Axis Resection (DP-CAR): As Always, it is All About Patient Selection. Annals of Surgical Oncology, 2019, 26, 703-704.	0.7	1
169	ASO Author Reflections: The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 3948-3949.	0.7	1
170	Neoadjuvant Chemotherapy in Pancreatic Cancerâ€”Reply. JAMA Surgery, 2021, 156, 398.	2.2	1
171	Thumbprinting Locally Advanced Pancreatic Cancer: Have We Developed the Optimal Staging System?. Annals of Surgical Oncology, 2021, 28, 5808-5810.	0.7	1
172	ASO Author Reflections: Accelerating the Learning Curve of Robotic Pancreatectomy and Gastrectomy Through a Composite Robotic Foregut Surgical Oncology Program. Annals of Surgical Oncology, 2022, 29, 286-287.	0.7	1
173	Pancreas cancer trials for early stage disease: Surgeons leading therapeutic cooperative group trials. Journal of Surgical Oncology, 2021, , .	0.8	1
174	The conundrum in endoscopic management of duodenal polyps: a tertiary cancer center experience. Expert Review of Gastroenterology and Hepatology, 2022, 16, 569-576.	1.4	1
175	Approaches to Retroperitoneal Dissection During Pancreatoduodenectomy. , 2018, , 213-227.		0
176	Pancreaticojejunostomy: How I Do It. , 2018, , 95-99.		0
177	Perioperative Clinical Trials for Pancreatic Cancer in the National Clinical Trials Network. Annals of Surgical Oncology, 2019, 26, 4173-4174.	0.7	0
178	ASO Author Reflections: It is Time to Prioritize Exercise in Pancreatic Cancer Survivorship. Annals of Surgical Oncology, 2021, 28, 2310-2311.	0.7	0
179	Commentary: Periadventitial dissection of the superior mesenteric artery at pancreatoduodenectomy for locally advanced pancreatic cancer. Surgery, 2021, 169, 1034-1035.	1.0	0
180	ASO Visual Abstract: Surgical Outcomes for Cancer Patients Undergoing Elective Surgery after Recovering from Mild to Moderate SARS-CoV-2 Infection. Annals of Surgical Oncology, 2021, 28, 591.	0.7	0

#	Article	IF	Citations
181	Abstract A40: Pancreatic cancer patient-derived orthotopic xenograft (PDOXâ„¢) is effectively targeted bySalmonella typhimuriumA1-R. , 2014, , .		0
182	Pancreatoduodenectomy with Concomitant Vascular Resection for Pancreas Cancer. , 2017, , 113-128.		0
183	Response to the Comment on â€œPostoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinomaâ€. Annals of Surgery, 2020, Publish Ahead of Print, e718-e719.	2.1	0
184	Cooperative Clinical Trials. Success in Academic Surgery, 2020, , 195-212.	0.1	0
185	ASO Author Reflections: Can We Measure â€˜Valueâ€™?. Annals of Surgical Oncology, 2022, , 1.	0.7	0
186	ASO Visual Abstract: WhatÂisÂâ€œValueâ€? Results of a Survey of Cancer Patients and Providers. Annals of Surgical Oncology, 2022, , 1.	0.7	0